We are live on
!
Find out more
RCM
RA Capital Management Portfolio holdings
AUM
$9.44B
1-Year Est. Return
157.3%
This Fund
S&P 500
This Quarter
Est. Return
+8.63%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$9.44B
AUM Growth
-$323M
(-3.3%)
Cap. Flow
-$311M
Cap. Flow
% of AUM
-3.3%
Top 10 Holdings %
Top 10 Hldgs %
61.29%
Holding
95
New
24
Increased
17
Reduced
2
Closed
10
Top Buys
| 1 |
SGP
SpyGlass Pharma
SGP
|
+$216M |
| 2 |
Wave Life Sciences
WVE
|
+$114M |
| 3 |
Zai Lab
ZLAB
|
+$106M |
| 4 |
Sarepta Therapeutics
SRPT
|
+$75.5M |
| 5 |
Nuvalent
NUVL
|
+$66.7M |
Top Sells
| 1 |
CDTX
Cidara Therapeutics
CDTX
|
+$743M |
| 2 |
RNAM
Avidity Biosciences
RNAM
|
+$623M |
| 3 |
ACLX
Arcellx
ACLX
|
+$82.6M |
| 4 |
BLTE
Belite Bio
BLTE
|
+$69.2M |
| 5 |
Invivyd
IVVD
|
+$42.3M |
Sector Composition
| 1 | Healthcare | 99.71% |
| 2 | Financials | 0.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Spyre Therapeutics
SYRE
$8.59B
| $81.8M | 0.87% |
1,621,620
| – | – |
|
|
EVMN
27
Evommune Inc
EVMN
$432M
| $80.3M | 0.85% |
3,494,638
+35,868
| +1% | +$811K |
|
|
CLYM
28
Climb Bio
CLYM
$758M
| $77.4M | 0.82% |
11,300,939
+7,111
| +0.1% | +$41K |
|
29
Solid Biosciences
SLDB
$948M
| $67.2M | 0.71% |
9,339,978
+3,528,555
| +61% | +$22.7M |
|
|
ARTV
30
Artiva Biotherapeutics
ARTV
$454M
| $63.5M | 0.67% |
9,853,302
| – | – |
|
|
DMRA
31
Damora Therapeutics
DMRA
$1.91B
| $62.1M | 0.66% |
+2,399,310
| New | +$61.7M |
|
32
Xencor
XNCR
$1.11B
| $59.1M | 0.63% |
+4,897,237
| New | +$60.8M |
|
|
LBRX
33
LB Pharmaceuticals
LBRX
$918M
| $54.5M | 0.58% |
2,208,604
| – | – |
|
|
JBIO
34
Jade Biosciences
JBIO
$1.3B
| $51.6M | 0.55% |
3,671,083
| – | – |
|
35
Acumen Pharmaceuticals
ABOS
$183M
| $49.5M | 0.52% |
20,992,669
+6,060,606
| +41% | +$15.5M |
|
36
4D Molecular Therapeutics
FDMT
$612M
| $47M | 0.5% |
5,049,779
-603,432
| -11% | -$5.25M |
|
37
Fulcrum Therapeutics
FULC
$239M
| $46.4M | 0.49% |
6,053,960
| – | – |
|
38
Capricor Therapeutics
CAPR
$1.2B
| $45.8M | 0.49% |
1,507,844
| – | – |
|
39
Century Therapeutics
IPSC
$384M
| $40.1M | 0.43% |
+17,754,430
| New | +$37.3M |
|
40
Olema Pharmaceuticals
OLMA
$1.04B
| $38.8M | 0.41% |
2,600,000
| – | – |
|
|
LENZ
41
LENZ Therapeutics
LENZ
$155M
| $38.2M | 0.41% |
4,178,823
| – | – |
|
42
Monopar Therapeutics
MNPR
$668M
| $36.6M | 0.39% |
667,207
| – | – |
|
43
PepGen
PEPG
$169M
| $35.5M | 0.38% |
20,064,545
| – | – |
|
44
Design Therapeutics
DSGN
$854M
| $31.6M | 0.34% |
2,972,973
+1,511,592
| +103% | +$15.3M |
|
45
Mirum Pharmaceuticals
MIRM
$7.37B
| $29.4M | 0.31% |
+318,554
| New | +$30M |
|
|
BIOA
46
BioAge Labs
BIOA
$1.01B
| $28.9M | 0.31% |
+1,650,648
| New | +$31.8M |
|
47
Lexeo Therapeutics
LXEO
$363M
| $28.7M | 0.3% |
5,000,000
| – | – |
|
48
Assembly Biosciences
ASMB
$530M
| $28.3M | 0.3% |
1,020,410
| – | – |
|
49
Rezolute
RZLT
$465M
| $28M | 0.3% |
9,180,000
| – | – |
|
|
AKTS
50
Aktis Oncology
AKTS
$1.39B
| $26.9M | 0.28% |
+1,503,084
| New | +$29.2M |
|
Similar funds
SCM
AIM
MIF
SIM
NPT
AC
PVI
WPL